Podrobno

Dislipidemija pri s presnovo povezanih boleznih jeter ter bolnikih s COVID-19
ID Kočar, Eva (Avtor), ID Rozman, Damjana (Mentor) Več o mentorju... Povezava se odpre v novem oknu

.pdfPDF - Predstavitvena datoteka. Vsebina dokumenta nedostopna do 01.04.2026.
MD5: 5D77EEB10F46177B63ACE14681D2F5A0

Izvleček
S presnovno motnjo povezana steatotična bolezen jeter (MASLD) je najbolj razširjena oblika kronične bolezni jeter na svetu. MASLD je tesno povezana z dislipidemijo, vendar nepopolno razumevanje molekularnih mehanizmov bolezni otežuje napoved poteka bolezni ter razvoj učinkovitih diagnostičnih in terapevtskih pristopov. Dislipidemija se pojavlja tudi pri bolnikih s COVID-19, pri čemer je njen obseg povezan z napredovanjem in izidom bolezni. Zaradi visoke zdravstvene in ekonomske obremenitve, ki jo povzročata MASLD in COVID-19, je iskanje novih biooznačevalcev posamezne bolezni izjemno pomembno. Osrednji namen doktorskega dela je bila opredelitev potencialnih tkivnih in krvnih biooznačevalcev različnih stopenj fibroze MASLD ter napredovanja in poteka bolezni COVID-19. Posvetlili smo se tudi preučevanju vpliva prekinjene biosinteze holesterola na sterolno sestavo membran in vezavo virusa SARS-CoV-2 na membrane celic gostitelja. Z analizo transkriptoma 60 vzorcev jeter bolnikov z različnimi stopnjami fibroze MASLD smo med skupinami opredelili devet diferenčno izraženih genov (AEBP1, ANKRD29, CPE, EFEMP1, ITGBL1, LUM, PTGDS, A2M, TRIM22). Na podlagi dodatnih računskih analiz ter pregleda objavljene literature smo razširili nabor tarčnih genov ter z metodo RT-qPCR na večji kohorti pacientov (N=141) eksperimentalno potrdili diferenčno izražanje 17 od skupno 27 genov. Poleg tega smo s tehnikami strojnega učenja zgradili klasifikacijski model, ki na podlagi treh kliničnih parametrov (indeks telesne mase, celokupni holesterol, število trombocitov) ter izražanju osmih genov (LUM, PTGDS, FBLN5, DPT, EFEMP1, STMN2, DCN, MMP2) razvrsti bolnike z začetnimi stopnjami fibroze MASLD (F0–F1/F2; AUC=0,84). S tarčno lipidomiko smo določili sterolni profil v serumu 62 hospitaliziranih bolnikov s COVID-19 ter podali vpogled v sterolne intermediate, predhodnike holesterola, med boleznijo COVID-19. Prišli smo do ugotovitve, da je biosinteza holesterola med potekom bolezni spremenjena. V primerjavi s pacienti, ki so imeli blag potek bolezni, so bile pri pacientih s hudim potekom COVID-19 spremembe izrazitejše, saj so bile statistično značilno spremenjene koncentracije večih sterolnih intermediatov (cimostenol, cimosterol, 24-dehidrolatosterol, dezmosterol, holesterol). S tehnikami strojnega učenja smo zgradili klasifikacijski model (N=164), ki presega obstoječe klinične ocene tveganja. Razvit model temelji na osmih lahko dostopnih kliničnih parametrih in z izjemno natančnostjo napove potek bolezni COVID-19 (AUC=0,96). Vključitev meritev podskupine sterolnih intermediatov izboljša občutljivost modela. Vpliv prekinjene biosinteze holesterola na sterolno sestavo membran in na vezavo proteina spike z membranami smo preučevali na modelnih celičnih linijah HepG2 z izbitimi geni za encime iz poskvalenskega dela biosinteze holesterola. Z metodama LC-MS/MS in konfokalno mikroskopijo smo pokazali, da prekinjena biosinteza holesterola vpliva na sterolno sestavo preučevanih celic ter na specifično vezavo fluorescenčne različice ostreolizina A6 na lipidne rafte. Za preučevanje vezave virusnega proteina spike z membrano smo z metodama rekombinantne DNA in afinitetne kromatografije uspešno izrazili in očistili receptorvezavno domeno (RBD) virusnega proteina spike. Pokazali smo, da se izražanje receptorja ACE2 med celičnimi linijami HepG2 različnih genotipov razlikuje, vendar vpliva prekinjene biosinteze holesterola na vezavo RBD-spike z membranami celic HepG2 različnih genotipov nismo uspeli potrditi. Raziskava je identificirala nove potencialne tkivne biooznačevalce posameznih stopenj fibroze MASLD in podala izhodišče za odkrivanje neinvazivnih biooznačevalcev bolezni v krvi. Prav tako je opredelila spremembe sterolnega profila v serumu hospitaliziranih bolnikov s COVID-19 ter izpostavila biooznačevalce poteka bolezni. Nenazadnje pa je raziskava podala tudi smernice za nadaljnje preučevanje vpliva prekinjene biosinteze holesterola na vezavo in vstop virusa SARS-CoV-2 v celice gostitelja.

Jezik:Slovenski jezik
Ključne besede:MASLD, COVID-19, SARS-CoV-2, dislipidemija, biosinteza holesterola, steroli, strojno učenje, biooznačevalci
Vrsta gradiva:Doktorsko delo/naloga
Organizacija:MF - Medicinska fakulteta
Leto izida:2025
PID:20.500.12556/RUL-169186 Povezava se odpre v novem oknu
Datum objave v RUL:16.05.2025
Število ogledov:382
Število prenosov:0
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Dyslipidemia in metabolic associated liver diseases and in COVID-19 patients
Izvleček:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent form of chronic liver disease worldwide. The disease is closely associated with dyslipidemia; however, the limited understanding of its molecular mechanisms hinders accurate prediction of disease progression and the development of effective diagnostic and therapeutic approaches. Dyslipidemia is also observed in COVID-19 patients, and its severity correlates with disease progression and outcome. Given the significant healthcare and economic burden of MASLD and COVID-19, the search for new biomarkers for both diseases is of utmost importance. The aim of the dissertation was to identify potential tissue and blood biomarkers for different stages of MASLD fibrosis and for the severity and progression of COVID-19. Additionally, we investigated how impaired cholesterol biosynthesis affects membrane sterol composition and the binding of the SARS-CoV-2 virus to host cell membranes. Through transcriptome analysis of 60 liver samples from patients at different fibrosis stages, we identified nine differentially expressed genes (AEBP1, ANKRD29, CPE, EFEMP1, ITGBL1, LUM, PTGDS, A2M, TRIM22) across various groups. Based on additional computational analyses and a review of the published literature, we expanded the set of target genes and experimentally validated the differential expression of 17 of the 27 genes in a larger patient cohort (N=141) using RT-qPCR. In addition, using machine learning techniques, we developed a classification model trained on three clinical parameters (body mass index, total cholesterol, and platelet count) and the expression of eight genes (LUM, PTGDS, FBLN5, DPT, EFEMP1, STMN2, DCN, MMP2) to stratify patients with early fibrosis stages (F0–F1/F2; AUC=0.84). Using targeted lipidomics, we determined the sterol profile in the serum of 62 hospitalized COVID-19 patients and provided insights into sterol intermediates, the precursors of cholesterol, during the course of COVID-19. Our findings indicate that cholesterol biosynthesis is altered during COVID-19. Compared to patients with a milder disease course, those with severe COVID-19 exhibited more pronounced changes, with statistically significant alterations in the concentrations of several sterol intermediates (zymostenol, zymosterol, 24-dehydrolathosterol, desmosterol and cholesterol). Using machine learning techniques, we have developed a classification system (N=164) that outperforms existing clinical risk assessment tools. Our model is based on eight readily accessible clinical parameters and predicts COVID-19 disease progression with exceptional accuracy (AUC=0.96). Adding measurements of a subset of sterol intermediates improves the sensitivity of the model. We also investigated the effect of impaired cholesterol biosynthesis on membrane sterol composition and spike protein binding to membranes using HepG2 model cell lines with knockout genes involved in the post-squalene part of cholesterol biosynthesis. Using LC-MS/MS and confocal microscopy, we demonstrated that impaired cholesterol biosynthesis alters the sterol composition of the investigated cells and affects the specific binding of the fluorescent variant of ostreolysin A6 to lipid rafts. To investigate the binding of the viral spike, we successfully expressed and purified the receptor-binding domain (RBD) of the spike protein using recombinant DNA techniques and affinity chromatography. Our results suggest that ACE2 receptor expression varies among HepG2 cell lines of different genotypes. However, we were unable to confirm the effect of impaired cholesterol biosynthesis on the binding of RBD spike protein to HepG2 cell membranes of different genotypes. The study identified novel potential tissue biomarkers for different stages of MASLD fibrosis and provided a basis for the discovery of non-invasive blood biomarkers for the disease. Additionaly, changes in the serum sterol profile of hospitalized COVID-19 patients were characterized and biomarkers associated with COVID-19 progression were identified. In addition, guidelines for future studies on the effects of impaired cholesterol biosynthesis on the binding and entry of the SARS-CoV-2 virus into host cells were established.

Ključne besede:MASLD, COVID-19, SARS-CoV-2, dyslipidemia, cholesterol biosynthesis, sterols, machine learning, biomarker

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj